Mean of the probabilities of ILI and 95% credibility interval for each strategy by baseline pVL.

<p>Strategy A: single standard dose+single standard dose booster; Strategy B: double dose+double dose booster; Strategy C: single standard dose+no booster; Strategy D: standard of care.</p

Model parameters.

<p>ILI: Influenza like illness; PY: Person-year; HRQoL: Health-related quality of life;</p><p>*Among pre-treated patients.</p><p>**Drawn from 2000/2001 estimates among a healthy elderly population <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0027059#pone.0027059-Sullivan1" target="_blank">[20]</a>.</p>#<p>Unsuppressed patients were treated with one new drug; percentage of patients transitioning within a one-year period.</p><p>***Derived from baseline HUI3 scores of CTN-237 participants.</p>##<p>In 2009$CDN. Included the costs of Derived from 5000 bootstrap re-samples of N = 31 ILI events captured in the CTN-237 database.</p

Monthly distribution of the probability of ILI.

<p>Weekly influenza surveillance report form CDC <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0027059#pone.0027059-Myliwska1" target="_blank">[22]</a>. 2008–2009 influenza season, week 39 ending October 3, 2009. Data shows only seasonal influenza and pandemic strain, 2009 influenza A (H1N1) virus, has been omitted.</p

Results of one-way sensitivity analyses.

<p>*Threshold for attaining 50% clinical protection for individuals with HIV.</p

Patient characteristics.

<p>pVL = HIV plasma viral load.</p

Cost-effectiveness acceptability curves.

<p>Cost-effectiveness acceptability curves.</p

Probability of HAI titre improvement^*: results from 1^st-stage analysis.

<p>*HAI Titre improvement was defined as HAI titre ever being greater than 1∶10 during follow-up assessments.</p

Kaplan Meier time to significant fibrosis stratified by sex.

<p>Kaplan Meier time to significant fibrosis stratified by sex.</p

Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).

<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use;</p><p>APRI, aspartate aminotransferase to platelet ratio; AST, aspartate aminotransferase; BMI, body mass index;</p><p>cART, combination antiretroviral; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.</p><p>^aSum of regimens >100% as some participants are on both PI, NNRTI and/or other cART.</p><p>^bFor HCVRNA VL only 166 (34/87 (39%) female and 132/221 (60%) male) had available quantitative HCV RNA values.</p><p>Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).</p

Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.

<p>Abbreviations: IDU, injection drug use; HCV, hepatitis C virus; cART, combination antiretroviral; PI, protease inhibitor;</p><p>NNRTI, non-nucleoside reverse transcriptase inhibitor; APRI, aspartate aminotransferase to platelet ratio;</p><p>BMI, body mass index; HR, hazard ratio; CI, confidence interval.</p><p>Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.</p